曲伏前列素滴眼液治疗继发性青光眼的临床观察  

A Clinical Observation of Travoprost (Travatan) in Treating Patients with Secondary Glaucoma

作　　者：马伟华[1] 崔瑞[1] 

机构地区：[1]河南省漯河市第三人民医院眼科,河南漯河462000

出　　处：《中国医药指南》2012年第19期48-49,共2页Guide of China Medicine

摘　　要：目的 观察曲伏前列素滴眼液（苏为坦）治疗继发性青光眼的有效性和安全性.方法 观察34 例（35 眼）继发性青光眼患者,A组19 例（20 眼）高度近视白内障术后高眼压（术前眼压正常）;B 组15 例（15 眼）眼球钝挫伤前房积血继发青光眼,所有患者单用或联合点用0.004% 曲伏前列素滴眼液,每晚1 次,随访12 周,观察眼压、视野及不良反应.结果 曲伏前列素滴眼液对两组患者均能显著降低眼压（P ＜ 0.05）,12 周后平均降眼压幅度7.5～10.1mmHg,视野缺损与治疗前比较无显著性差异（P ＞ 0.05）.不良反应主要为结膜充血.结论 曲伏前列素滴眼液能显著降低继发性青光眼眼压,安全有效,有较好的耐受性.Objective To evaluate the effectiveness and safety oftravoprost in treating patients with secondary glaucoma. Methods 35 eyes of 34 secondary glaucoma patients, including 19 high myopia cases （20 eyes） （group Ⅰ ） of higher IOP after ECCE with IOL implantation （preoperative IOP in normal） ; 15 cases （ 15 eyes） （group Ⅱ ） of contusion hyphema with secondary glaucoma, were dosed with travoprost as adjunctive therapy once daily. The observed signs included lOP, visual field and adverse reaction. The follow-up duration was 12 weeks. Results Travoprost reduced IOP significantly （ P〈0.05） . After 12 weeks, IOP reductions ranged from 7.5-10.1mmHg, and mean defect in visual field didn＇t change significantly compared with that of p retreaanent （P〉0.05） . The most adverse reaction was mild to moderate conjunctival hyperemia. Conclusion Travoprost reduced IOP significantly in secondary glaucoma patients, and was safe and well tolerated.

关 键 词：曲伏前列素 继发青光眼 

分 类 号：R775[医药卫生—眼科]